Data gathered: December 26
Alternative Data for PTC Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 32 | Sign up | Sign up | Sign up |
| Sentiment | 75 | Sign up | Sign up | Sign up |
| Webpage traffic | 16,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| Patents | 125 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 137 | Sign up | Sign up | Sign up |
| Facebook Followers | 5,793 | Sign up | Sign up | Sign up |
| Instagram Followers | 3,462 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,187 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,319 | Sign up | Sign up | Sign up |
| Twitter Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 56 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,146 | Sign up | Sign up | Sign up |
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
| Price | $45.84 |
| Target Price | Sign up |
| Volume | 278,520 |
| Market Cap | $3.5B |
| Year Range | $25.21 - $52.07 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 22 - Yahoo |
 |
Geode Capital Management LLC Has $66.74 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)December 22 - ETF Daily News |
|
PTC Therapeutics (NASDAQ:PTCT) Downgraded by StockNews.com to “Hold”December 19 - ETF Daily News |
 |
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich AtaxiaDecember 18 - Yahoo |
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)December 17 - Finnhub |
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 17 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 198M | 76M | 121M | -107M | -95M | -1.390 |
| Q2 '24 | 187M | 73M | 114M | -99M | -83M | -1.270 |
| Q1 '24 | 210M | 129M | 81M | -92M | -33M | -1.200 |
| Q4 '23 | 191M | -83M | 274M | -156M | -80M | -0.240 |
| Q3 '23 | 197M | 162M | 34M | -133M | -107M | -1.760 |
Insider Transactions View All
| Boulding Mark Elliott filed to sell 92,389 shares at $54.1. December 4 '24 |
| Boulding Mark Elliott filed to sell 92,389 shares at $53. December 4 '24 |
| Boulding Mark Elliott filed to sell 92,389 shares at $54.1. December 4 '24 |
| Boulding Mark Elliott filed to sell 92,477 shares at $53.1. December 4 '24 |
| Boulding Mark Elliott filed to sell 93,794 shares at $53.1. December 4 '24 |
Similar companies
Read more about PTC Therapeutics (PTCT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of PTC Therapeutics?
The Market Cap of PTC Therapeutics is $3.5B.
What is the current stock price of PTC Therapeutics?
Currently, the price of one share of PTC Therapeutics stock is $45.84.
How can I analyze the PTCT stock price chart for investment decisions?
The PTCT stock price chart above provides a comprehensive visual representation of PTC Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling PTC Therapeutics shares. Our platform offers an up-to-date PTCT stock price chart, along with technical data analysis and alternative data insights.
Does PTCT offer dividends to its shareholders?
As of our latest update, PTC Therapeutics (PTCT) does not offer dividends to its shareholders. Investors interested in PTC Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of PTC Therapeutics?
Some of the similar stocks of PTC Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.